THE Australian Medicinal Cannabis Association (AMCA) and Medicinal Cannabis Industry Australia (MCIA) have called for cross-sector collaboration among healthcare stakeholders as public submissions to the Therapeutic Goods Administration (TGA) consultation on the safety and regulatory oversight of unapproved medicinal cannabis products close.
"Reform must be guided by science, patient experience and a shared commitment to quality and safety," said Teresa Nicoletti, Chair of AMCA.
The above article was sent to subscribers in Pharmacy Daily's issue from 22 Oct 25
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 22 Oct 25
